 Skye Bioscience Inc OTCQB:SKYE, a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, said it has selected NextPharma as its contract manufacturing organization CMO for its phase 2 clinical trial material. NextPharma is a European pharmaceutical contract development and manufacturing organization that supplies products globally from its nine sites. 